The initial public offering (IPO) of Gaudium IVF and Women Health Ltd, a fertility services provider, saw strong investor interest on Day 2 of bidding, with retail and non-institutional investors driving demand. The IPO, which started on February 20, 2026 and is set to finish on February 24, 2026, attracted bids significantly beyond the shares on sale, indicating strong interest ahead of its planned debut later this month. The market’s strong response shows investor interest in specialist healthcare categories, especially as Gaudium IVF becomes the first pure-play fertility care company to enter India’s public markets.
By mid-day on the second day of subscription, the Rs 165-crore IPO was subscribed 1.67 times, according to National Stock Exchange (NSE) data, with 2.44 crore equity shares bid against the 1.46 crore shares on offer. The retail individual investor (RII) portion saw particularly strong interest, with subscription levels reaching more than 2.4 times its allocation, while the non-institutional investor (NII) category registered around 2.18 times subscription. However, qualified institutional buyers (QIBs) showed minimal participation so far.
The IPO’s price band was fixed at ₹75-79 per share, valuing the company at around ₹575 crore on a pre-issue basis. Before public subscription opened, Gaudium IVF had already raised ₹49.5 crore from anchor investors, a group of institutional backers that typically include funds and high-net-worth investors who take early positions in the issue.
Strong Retail and NII Momentum:
The retail and NII segments were clearly the main drivers of investor excitement for Gaudium IVF’s IPO, as they combined to account for the majority of the subscriptions on Day 2. The IPO offers many retail investors a chance to get involved in India’s growing fertility care industry, a specialized medical field that has seen a surge in demand as a result of increased access to and awareness of assisted reproductive technologies like intrauterine insemination (IUI), in-vitro fertilization (IVF), and related procedures.
The high level of retail involvement shows that smaller investors see value in a healthcare company with growth prospects tied to demographic trends and rising fertility service affordability. Similarly, non-institutional investors, including high-net-worth individuals and other non-retail participants, have expressed strong interest, showing their belief in the sector’s long-term potential and Gaudium IVF’s market stance.While the qualified institutional category has received few bids to yet, this is not uncommon for smaller IPOs, where retail and NII demand often drives early momentum. The strong traction in the retail and NII buckets may attract additional interest from institutional participants as the subscription period develops.
Grey Market Premium Signals Potential Listing Gains:
In unofficial markets tracking grey market premiums (GMP), Gaudium IVF shares are commanding attractive premiums, signalling positive expectations around its listing performance. According to platforms tracking grey market activity, the company’s shares were trading at premiums ranging from roughly ₹7.5 to ₹8.50 per share above the issue price. This implies a potential listing gain of around 10-11%, should these unofficial prices translate into actual market valuations upon debut.
GMP provides an informal indicator of investor sentiment ahead of an IPO’s official listing. A healthy premium often suggests that the market expects strong demand for the stock when it begins trading on stock exchanges such as the BSE and NSE both of which are expected to host Gaudium IVF’s shares beginning on 27 February 2026, following the likely allotment on 25 February 2026.
Outlook and Investor Considerations
With subscription figures closing in on full subscription well ahead of the IPO’s scheduled close, the early bidding activity positions Gaudium IVF as a noteworthy listing in the broader 2026 IPO calendar. The strong interest from retail and NII categories, backed by a promising GMP, suggests positive sentiment and confidence among investors in the company’s business model and growth prospects.
Investors will be watching carefully as the subscription period ends on February 24 and the allotment and listing stages begin. Finally, the performance of Gaudium IVF’s shares following their offering will provide clearer indicators of market enthusiasm for healthcare IPOs and the valuations investors are willing to place on new specialist service providers. Overall, Gaudium IVF’s fully subscribed status on Day 2 is a promising start for its public market debut, paving the way for its admission into India’s increasing universe of publicly traded healthcare enterprises.
